Reimbursed Care Access in Georgia

Currently classified as a strictly controlled substance under Georgia state controlled‑substances law (Schedule I), with no authorized medical use outside of approved clinical research. See Georgia Code O.C.G.A. §16‑13‑25 which lists psilocybin and psilocyn as Schedule I substances. #

Currently classified as a strictly controlled substance under Georgia state scheduling (Schedule I) with no authorized medical use outside of approved clinical research. Georgia law explicitly lists 3,4‑methylenedioxymethamphetamine (MDMA) in Schedule I. #

Esketamine nasal spray (branded SPRAVATO®) is FDA‑approved for treatment‑resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior; because of risks (sedation, dissociation, potential misuse) it is only available through a REMS program and must be administered in certified healthcare settings. # #

Reimbursement/access in Georgia: SPRAVATO® is delivered in REMS‑certified clinics and coverage is handled on a plan‑by‑plan basis. Many commercial insurers, Medicare (Part B/Part D/MA plan policies vary), and some Medicaid managed‑care plans cover SPRAVATO® when prior‑authorization criteria are met (typically documentation of treatment‑resistant depression defined by inadequate response to ≥2 antidepressant trials, documentation of monitoring capacity and REMS enrollment). Georgia Medicaid managed plans list SPRAVATO® in pharmacy/medical policy documents (providers should confirm the member’s specific Medicaid plan and prior‑authorization requirements). Example managed‑care pharmacy policy listings in Georgia show SPRAVATO® as a listed drug requiring authorization—clinics routinely secure prior authorization and must bill under appropriate medical/pharmacy codes consistent with payer rules. # #

Practical notes for clinicians and patients in Georgia: clinics must be REMS‑certified and observe post‑dosing monitoring (≥2 hours). Payers commonly require: (1) documentation of diagnosis (MDD/TRD), (2) prior trials of oral antidepressants and/or evidence of treatment resistance, (3) REMS enrollment and site certification, and (4) demonstration that the site can meet monitoring/safety requirements. Coverage decisions and patient cost‑sharing vary; prior authorization and utilization review are routine, and some clinics report variability with specific Medicaid and commercial plans—confirm benefits and billing codes (clinic billing teams often help secure authorizations). # #

Intravenous (and in some cases intranasal or intramuscular) racemic ketamine is widely used off‑label in Georgia clinics for depression, PTSD, and other psychiatric indications but it is not FDA‑approved for these psychiatric indications; as a result, coverage and reimbursement are inconsistent and commonly limited. The FDA has not approved racemic ketamine for depression (ketamine remains an approved anesthetic agent), and most ketamine infusion programs operate in the private pay / self‑pay market or rely on limited case‑by‑case insurer approval. # #

Detailed practical/regulatory context for Georgia: Providers offering off‑label ketamine infusions must follow standard state medical practice rules (board‑certified oversight, informed consent, monitoring for adverse effects). Because ketamine for depression is not an FDA‑labeled psychiatric indication, most commercial insurers and Medicare do not provide routine coverage for IV ketamine infusions; exceptions occur when services are billed under specific medical necessity claims and the insurer has an emergent/experimental policy allowing coverage. Many clinics therefore rely on self‑pay, limited insurance reimbursement for associated services (e.g., physician visits, monitoring) or sparse prior‑authorization approvals. Clinics in Georgia commonly require pre‑treatment psychiatric evaluation, documentation of prior treatment failures, and detailed consent describing off‑label status and potential risks. #

Currently classified as a strictly controlled substance under Georgia state drug scheduling (DMT is a Schedule I substance) with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under Georgia state controlled‑substances law, with no authorized medical use outside of approved clinical research. (No routine medical or reimbursement pathway exists in Georgia.) #

Currently classified as a strictly controlled substance under Georgia law with no authorized medical use outside of approved clinical research and no standard reimbursement pathway; clinical use (e.g., addiction clinics) in other jurisdictions does not translate to legal access or coverage in Georgia. #

Because ayahuasca contains DMT (a Schedule I substance in Georgia), ayahuasca and DMT‑containing brews are illegal for general use and have no authorized medical/reimbursed pathway outside of approved research or an extremely narrow, court‑granted religious exemption (which is rare and case‑specific). Currently there is no routine medical authorization or insurance reimbursement for ayahuasca use in Georgia. #

Mescaline and mescaline‑containing cacti (except in narrowly defined tribal/religious contexts under federal case law) are classified as controlled substances in Georgia (Schedule I) and have no authorized medical or reimbursed use outside approved clinical research. #

The 2C‑family substituted phenethylamines fall under Georgia’s controlled‑substances listings (Schedule I / listed synthetic hallucinogens) and are illegal with no authorized medical use or reimbursement pathway outside of properly authorized research. #